Overview

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

Status:
RECRUITING
Trial end date:
2026-02-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.
Phase:
PHASE1
Details
Lead Sponsor:
Rezubio Pharmaceuticals Co., Ltd.